Skip to main content
. Author manuscript; available in PMC: 2014 Feb 10.
Published in final edited form as: Phys Med Biol. 2012 Mar 9;57(7):N65–N81. doi: 10.1088/0031-9155/57/7/N65

Figure 5.

Figure 5

a) T1-weighted MR image of the entire mouse head verifying BBB opening using gadolinium enhancement and b) Fluorescence image magnified in the region of interest where the highest gadolinium enhancement was detected (white rectangle) in two separate murine brains, one with fluorescently tagged (Alexa Fluor) i) GDNF (Invitrogen, Inc.) and the other with ii) Neurturin (courtesy of Judith P. Golden, Ph.D., Washington University Medical Center and Invitrogen, Inc.) were systemically administered using the same methods as for the BDNF study except for the target being the caudate putamen instead of the hippocampus. No statistical or immunohistochemistry studies were performed in these two cases to determine the downstream effects.